Get started
Author

Tineke Casneuf

Observed names: Casneuf T, Casneuf Tineke, Casneuf, T., Casneuf, Tine, Casneuf, Tineke, T. Casneuf, Tine Casneuf
Institution: Argenx (Belgium)
Observed institutions: Janssen (Belgium), Genmab (United States), Vlaams Instituut voor Biotechnologie, Ghent University, St Vincent's Hospital Melbourne, VIB-UGent Center for Plant Systems Biology, Genmab (Netherlands), Argenx (Belgium), Janssen Research & Development (United States), Amsterdam UMC Location Vrije Universiteit Amsterdam
ORCID: 0009-0005-8574-1231
Observed ORCID: 0009-0005-8574-1231
OpenAlex ID: A5011533368
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
2016 · Jakub Krejcik, Tineke Casneuf, et al. · Blood · 956
PDF
Modeling gene and genome duplications in eukaryotes
2005 · Steven Maere, Stefanie De Bodt, et al. · Proceedings of the National Academy of Sciences · 927
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
2016 · Inger S. Nijhof, Tineke Casneuf, et al. · Blood · 393
PDF
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
2018 · Andrew Spencer, Suzanne Lentzsch, et al. · Haematologica · 268
PDF
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
2017 · Tineke Casneuf, Xu Steven Xu, et al. · Blood Advances · 231
Unraveling Transcriptional Control in Arabidopsis Using cis-Regulatory Elements and Coexpression Networks
2009 · Klaas Vandepoele, Mauricio Quimbaya, et al. · PLANT PHYSIOLOGY · 229
PDF
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
2018 · Meletios A. Dimopoulos, Jesus San-Miguel, et al. · Haematologica · 213
PDF
Nonrandom divergence of gene expression following gene and genome duplications in the flowering plant Arabidopsis thaliana
2006 · Tineke Casneuf, Stefanie De Bodt, et al. · Genome biology · 199
PDF
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
2020 · Mark Bustoros, Romanos Sklavenitis-Pistofidis, et al. · Journal of Clinical Oncology · 186
PDF
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
2018 · Homer C. Adams, Frederik Stevenaert, et al. · Cytometry Part A · 163
PDF
A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
2013 · Peter M. Voorhees, Robert F. Manges, et al. · British Journal of Haematology · 147
PDF
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
2020 · Tineke Casneuf, Homer C. Adams, et al. · Leukemia · 121
PDF
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
2021 · Hervé Avet-Loiseau, Jesus San-Miguel, et al. · Journal of Clinical Oncology · 94
PDF
In situ analysis of cross-hybridisation on microarrays and the inference of expression correlation
2007 · Tineke Casneuf, Yves Van de Peer, et al. · BMC Bioinformatics · 71
PDF
Quantitative RNA expression analysis with Affymetrix Tiling 1.0R arrays identifies new E2F target genes
2008 · Naïra Naouar, Klaas Vandepoele, et al. · The Plant Journal · 70
Identification of novel regulatory modules in dicotyledonous plants using expression data and comparative genomics
2006 · Klaas Vandepoele, Tineke Casneuf, et al. · Genome biology · 61
PDF
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
2022 · Suzette Girgis, Shun Xin Wang Lin, et al. · Blood Advances · 55
Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
2022 · Diana Cortes-Selva, Tineke Casneuf, et al. · Blood · 47
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)
2016 · Christopher Chiu, Tineke Casneuf, et al. · Blood · 43
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
2020 · Katja Weisel, Andrew Spencer, et al. · Journal of Hematology & Oncology · 42
PDF
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
2023 · Christie P.M. Verkleij, Kristine A. Frerichs, et al. · HemaSphere · 37
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux
2017 · Meletios A. Dimopoulos, Darrell J. White, et al. · Blood · 36
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes
2022 · Mark Bustoros, Shankara Anand, et al. · Nature Communications · 35
PDF
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor
2016 · Maria-Victoria Mateos, Jane Estell, et al. · Blood · 34
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
2016 · Hervé Avet-Loiseau, Tineke Casneuf, et al. · Blood · 32
Works count: 103
Citation count: 5,013
H-index: 27
I10-index: 37
Year
Topic
Type